Stocks closed mixed as blue chips hit another record high but tech names tumbled on the potential for tighter U.S. restrictions on chip sales to China.
The U.S. presidential campaign season is already sending shockwaves through capital markets, notes José Torres, senior economist at Interactive Brokers.
"Semiconductor shares are getting hammered on news that Trump isn't happy with the technology sector's warmth toward Beijing," Torres writes in a note to clients. "Meanwhile, President Biden is rushing to potentially implement the harshest of penalties to chip firms that trade with China to toughen up on the geopolitical front and possibly shore up his dwindling odds of reelection."
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Concerns about additional curbs on sales of chips to China sent semiconductor stocks reeling. Magnificent 7 stock Nvidia (NVDA) dropped 6.6%, with Broadcom (AVGO, -7.9%), Advanced Micro Devices (AMD, -10.2%), Micron Technologies (MU, -6.3%) and several other sector names moving in sympathy.
As a result, the tech-heavy Nasdaq Composite tumbled 2.8% to settle at 17,996, while the broader S&P 500 fell 1.4% to 5,588. The blue-chip Dow Jones Industrial Average, however, set its 22nd record close or the year with a 0.6% gain to 41,198.
Today's divergent market action is raising questions about the sustainability of the current bull market. As Interactive Brokers' Torres notes, much of 2024's equity gains have come from "a handful of names currently under direct threat" from political campaigning.
"An important question is if the rest of the market, which generally lacks thrilling tales on a relative basis, can offset the waning momentum in the Magnificent 7 stocks," the economist says.
J&J helps the Dow
Johnson & Johnson (JNJ, +3.7) was a leading gainer among all 30 Dow Jones stocks after posting better-than-expected earnings. The pharmaceutical giant reported earnings per share (EPS) of $2.82 for the second quarter vs analysts' average estimate of $2.71. Revenue topped $22.3 billion, which was essentially in line with estimates.
Although Johnson & Johnson has long been one of the best dividend stocks for dependable dividend growth, its returns have been less than stellar. Indeed, JNJ trails the broader market for the year to date and has generated negative annualized total returns for the past one- and three-year periods.
Acquisitions, spin-offs and other moving parts make it tough for analysts to update their models. That's partly why the Street is sort of split on the JNJ at current levels.
Of the 23 analysts covering JNJ surveyed by S&P Global Market Intelligence, seven rate it at Strong Buy, five say Buy and 11 have it at Hold. That works out to a consensus recommendation of Buy, albeit with tepid conviction at best.
Related content
- Why Amazon Stock Is the Biggest Bargain on Amazon Prime Day
- If You'd Put $1,000 Into Amazon Stock 20 Years Ago, Here's What You'd Have Today
- All 30 Dow Jones Stocks Ranked: The Pros Weigh In
-
December Fed Meeting: Live Updates and CommentaryThe December Fed meeting is one of the last key economic events of 2025, with Wall Street closely watching what Chair Powell & Co. will do about interest rates.
-
This Is Why Investors Shouldn't Romanticize BitcoinInvestors should treat bitcoin as the high-risk asset it is. A look at the data indicates a small portfolio allocation for most investors would be the safest.
-
I'm a Federal Benefits Pro: I Answer These 2 Questions a LotMany federal employees ask about rolling a TSP into an IRA and parsing options for survivor benefits, both especially critical topics.
-
December Fed Meeting: Live Updates and Commentary
The December Fed meeting is one of the last key economic events of 2025, with Wall Street closely watching what Chair Powell & Co. will do about interest rates.
-
Why Investors Shouldn't Romanticize Bitcoin, From a Financial Planner
Investors should treat bitcoin as the high-risk asset it is. A look at the data indicates a small portfolio allocation for most investors would be the safest.
-
I'm a Financial Pro Focused on Federal Benefits: These Are the 2 Questions I Answer a Lot
Many federal employees ask about rolling a TSP into an IRA and parsing options for survivor benefits, both especially critical topics.
-
Private Credit Can Be a Resilient Income Strategy for a Volatile Market: A Guide for Financial AdvisersAdvisers are increasingly turning to private credit such as asset-based and real estate lending for elevated yields and protection backed by tangible assets.
-
5 RMD Mistakes That Could Cost You Big-Time: Even Seasoned Retirees Slip UpThe five biggest RMD mistakes retirees make show that tax-smart retirement planning should start well before you hit the age your first RMD is due.
-
I'm a Wealth Adviser: My 4 Guiding Principles Could Help You Plan for Retirement Whether You Have $10,000 or $10 MillionRegardless of your net worth, you deserve a detailed retirement plan backed by a solid understanding of your finances.
-
A Retirement Triple Play: These 3 Tax Breaks Could Lower Your 2026 BillGood news for older taxpayers: Standard deductions are higher, there's a temporary 'bonus deduction' for older folks, and income thresholds have been raised.
-
If You're Retired or Soon-to-Be Retired, You Won't Want to Miss Out on These 3 OBBB Tax BreaksThe OBBB offers some tax advantages that are particularly beneficial for retirees and near-retirees. But they're available for only a limited time.
